News

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The Senior Director and Head of Technology Development at Epic Bio discussed potential applications of the new technology.

The case study was recently published in the Proceedings of the National Academy of Sciences.

An investigator noted challenging side effects related to immunosuppressant treatment.

The responses seen in the 9 patients included 3 complete responses (CRs), 2 very good partial responses, and 4 partial responses.

The medical director of clinical development at AskBio discussed the progress of an early clinical trial of AB-1002.

Treated participants have achieved some mild improvements on MDS-UPDRS Part III at 18 months posttreatment.

In terms of safety, SNK02 was characterized as “well-tolerated”.

The deputy director, Division of Rare Diseases Research Innovation, NCATS, NIH, discussed areas that the agency is targeting.

Earlier and prophylactic interventions have enabled low rates and severity of AEs in recent years of administration.

On the other hand, enhanced lymphodepletion increased incidence and severity of CRS and infection.

The scientist from Krembil Research Institute shared takeaways from the session she chaired.

There was a 98% (2.7% SD) mean reduction in monthly HAE attack rate through the patients’ most recent assessment.

Review top news and interview highlights from the week ending June 14, 2024.

The subgroup analysis also looked at safety outcomes.

The medical oncologist and clinical director of Myeloma Cellular Therapies at Dana-Farber Cancer Institute emphasized promising safety in patients with high-risk disease.

Among 10 patients who were treated with INB-100 in the trial, all 10 (100%) maintained their state of CR at 12 months or more posttreatment.

Eleven of 12 efficacy-evaluable patients with SLE and LN have met the DORIS criteria for complete remission.

Pfizer additionally noted that the trial missed the mark on key secondary end points.

The pediatric neurologist at Nemours Children’s Health discussed next steps in the field to fully enable the benefits of gene therapy.

In observance of Myasthenia Gravis Awareness Month, held annually in June, we took a look back at a year of progress in bringing CAR-T to this autoimmune disease.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The lead scientist at Percheron Therapeutics discussed research on antisense oligonucleotide therapies in mouse models of DMD.

AOC 001 previously demonstrated benefit in patients in the phase 2 MARINA trial.

The cofounder and chief scientific officer at Earli discussed the company’s unique approach to cancer diagnosis.

The FDA granted the designation after reviewing safety and efficacy data from phase 1 of the trial.

Ineka Whiteman, PhD, head of research and medical affairs, BDSRA Australia, discussed what has occurred in the field of Batten disease gene therapy in the past year.

The director of the Mount Sinai Fuster Heart Hospital discussed how artificial intelligence complements data-driven research.